Bexarotene-d4

Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069) . Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

Product Specifications

CAS Number

[2182068-00-2]

Product Name Alternative

LGD1069 D4

UNSPSC

12352005

Hazard Statement

H302

Target

Autophagy; RAR/RXR

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.51

Solubility

10 mM in DMSO|DMF : ≥ 20mg/mL|DMSO : ≥ 10mg/mL|Ethanol : ≥ 0.5mg/mL

Smiles

CC1(C2=C(C(C)(CC1)C)C=C(C(C(C3=C([2H])C([2H])=C(C([2H])=C3[2H])C(O)=O)=C)=C2)C)C

Molecular Formula

C24H24D4O2

Molecular Weight

352.50

Precautions

H302

References & Citations

[1]Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012 May;92 (3) :258-63. doi: 10.2340/00015555-1359.|[2]Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900 (18) 30607-2.|[3]Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol. 2012 Jan;4 (1) :56-60.|[4]Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. Neoplasma. 2012;59 (4) :469-74.|[5]Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C.